About fibrogen inc - FGEN
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
FGEN At a Glance
FibroGen, Inc.
350 Bay Street
San Francisco, California 94133
| Phone | 1-415-978-1200 | Revenue | 29.62M | |
| Industry | Pharmaceuticals: Major | Net Income | -47,579,000.00 | |
| Sector | Health Technology | Employees | 225 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
FGEN Valuation
| P/E Current | 0.215 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.788 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.05 |
| Enterprise Value to Sales | 4.546 |
| Total Debt to Enterprise Value | 0.67 |
FGEN Efficiency
| Revenue/Employee | 131,648.889 |
| Income Per Employee | -211,462.222 |
| Receivables Turnover | 1.022 |
| Total Asset Turnover | 0.093 |
FGEN Liquidity
| Current Ratio | 1.474 |
| Quick Ratio | 1.45 |
| Cash Ratio | 0.379 |
FGEN Profitability
| Gross Margin | 47.466 |
| Operating Margin | -442.126 |
| Pretax Margin | -517.764 |
| Net Margin | -160.626 |
| Return on Assets | -47.989 |
| Return on Equity | N/A |
| Return on Total Capital | 113.076 |
| Return on Invested Capital | N/A |
FGEN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -66.626 |
| Total Debt to Total Assets | 42.05 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -66.601 |